Baxter International Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andrew P. Hider
- Full Time Employees
- 37,500
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- One Baxter Parkway Deerfield IL United States 60015
- IPO Date
- May 15, 1961
- CIK
- 0000010456
- Website
- baxter.com
- Similar Companies
- Business
- Baxter International Inc specializes in medical products and therapies, healthcare system technologies, and pharmaceuticals. The company's main products include advanced surgical technologies under its Advanced Surgery division, infusion therapies and intravenous delivery systems under Infusion Therapies and Technologies, and hospital pharmaceuticals focusing on pain management, critical care, anti-infection, and oncology. Its Healthcare Systems and Technologies segment operates through divisions such as Front Line Care, Digital Platform and Innovations, Care and Connectivity Solutions, and Global Services. Baxter serves healthcare providers globally, offering products used at the hospital bedside, operating rooms, intensive care units, home care, and alternate care settings. Founded in 1931 and headquartered in Deerfield, Illinois, Baxter operates worldwide and emphasizes innovation to improve patient outcomes and operational efficiency. Recently, Baxter has undergone significant strategic transformations including the spin-off of its Renal Care and Acute Therapies global business units to establish a separate publicly traded company, streamlining its commercial and manufacturing footprint to enhance business performance, and reviewing strategic alternatives for its BioPharma Solutions business. In 2025, the company appointed Andrew Hider as CEO to advance continuous improvement and sustainable growth. Baxter launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation connected patient monitoring device, and achieved recognition with a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative in categories including IV Solutions, Nutrition Solutions, and Premix Drugs. The company also completed the integration of its Hill-Rom acquisition and continues to focus on operational simplification by reducing distribution centers and enhancing digital health solutions. Baxter reported third-quarter 2025 sales growth driven by Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments with ongoing investments in R&D to support steady product launches and innovation.
Company News
What Baxter International (BAX) Said on Its Q3 Earnings Call
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
Why Is Baxter Stock Trading Lower on Thursday?
Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates
Baxter Reports Third-Quarter 2026 Results
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
20,728 Shares of Baxter International Inc. $BAX Acquired by Cohen Klingenstein LLC
Baxter International: The Vantive Transition Complicates Margin Recovery
Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)
Baxter to Host Third-Quarter 2026 Financial Results Conference Call for Investors
Are Investors Undervaluing Baxter International (BAX) Right Now?
Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?
Baxter Releases Inaugural Connected Hospital Report
Baxter International Inc. (NYSE:BAX) Stock Now Rated “Hold” by Wall Street Analysts
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Bank of America Corp DE Makes New Investment in Baxter International Inc. $BAX
Baxter International Inc. $BAX Shares Bought by NewEdge Advisors LLC